Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2025-12-25 @ 11:56 PM
Study NCT ID:
NCT07240194
Status:
RECRUITING
Last Update Posted:
2025-11-20
First Post:
2025-09-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-09-01
Start Date Type:
ACTUAL
Primary Completion Date:
2028-12-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2025-09-25
First Submit QC Date:
None
Study First Post Date:
2025-11-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-19
Last Update Post Date:
2025-11-20
Last Update Post Date Type:
ESTIMATED